Sign In

Gynecologic Cancers

RUBY Long-Term Analysis Raises a New Question in Advanced Endometrial Cancer: Are Some Patients Being Cured?

Dr. Natalie Rafaeli

Excited But Cautious: Gynecological Oncologists Want Antibody-Drug Conjugate ‘Mo‑Rez’ Moved Into Later Trials ASAP

Kavontae Smalls

New FDA Approval: Relacorilant Plus Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Elahere Has Become a Practice-Changing Option for Platinum-Resistant, FRα-Positive Ovarian Cancer

Mirvetuximab Soravtansine (Elahere) Report Card: Three Years Of Real-World Data

SurvivorNet Staff

pink abstract cell design

Studies Indicate Lynparza Extends Life of Patients with Advanced Stage Ovarian Cancer

Dr. Rodrigo C. Leão Edelmuth,

Hospital Israelita Albert Einstein

Which Ovarian Cancer Patients Should Get PARP Inhibitor Maintenance Therapy?

Dr. Stephanie Wethington

Evaluating Risks vs. Benefits of PARP Inhibitors for Ovarian Cancer Patients

Dr. Stephanie Wethington

Which Ovarian Cancer Patients Should Receive Newly-Approved Elahere & What are the Risks?

pink abstract cell design

Next-Generation FRα-Directed Agents in Ovarian Cancer: What Sofetabart Mipitecan (LY4170156) Developments Mean For Practice

Dr. Kaique Filardi

Strategies for Deciding When to Use PARP Inhibitors for Ovarian Cancer Maintenance

Dr. Stephanie Wethington

Doctors Treating Minority Ovarian Cancer Patients May Not Be Aware of Their Own Implicit Biases

Dr. Dana Chase,

UCLA

To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring Progression-Free Survival and Side Effects Into the Decision

Dr. Bobbie Rimel